Skip to main content

BIO Europe 2020



This year alone, Certara is delivering 40+ disease specific assessments for US Market success.  Would your program benefit from these key deliverables?

  • Leverage our wide in-house therapeutic expertise to pressure-test registration, reimbursement, and commercialization assumptions.
  • Achieve rapid turnaround for tight due diligence timelines. 
  • Validate your deal structures with our quantitative net revenue forecasting, adjusting for critical pricing and access scenarios across key payer types.

Are you seeking proven expertise on the shifting pricing and reimbursement environment in the US?

Contact us today for a commercial assessment for new opportunities or pipeline assets, no-charge to Bio-Europe attendees!



Contact a Certara Biotech expert Today:

Oliver Leatham
Vice President,
Value & Access Services

Patrick Smith
Sr. Vice President,
Integrated Practice
Areas (Global)

Gary Kusha
Vice President
Business Development

Paul Gallagher
Vice President,
US Market Access Strategy

Maximilian Vargas
Sr. Director,
US Access and Account Management

Ulrich Neumann
Sr. Director,
US Access & Commercial Strategy

Powered by GlobalLink OneLink Software